Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients

European Journal of Preventive Cardiology

Volumn 14, Issue 3, 2007, Pages 438-440

  Huang, Chien Fang ^a   li, Tsai Chung ^a   Lin, Cheng Chieh ^a   Liu, Chiu Shong ^a   Shih, Hung Chang ^b   Lai, Ming May ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

hyperlipidemia; lipid ratio; red yeast rice

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLANT MEDICINAL PRODUCT; RED YEAST RICE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONASCUS PURPUREUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RICE; TREATMENT DURATION; TREATMENT OUTCOME; YEAST;

ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL PRODUCTS; CAPSULES; CHOLESTEROL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; MONASCUS; PHYTOTHERAPY; TREATMENT OUTCOME;

EID: 34250620912     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32801da137     Document Type: Article

References (8)

1. William B, Poulter NR, Brown MJ, Davis M, McInnes* GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139–185.
2. Goldstein MR, Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis. Am J Med 2000; 109: 72–73.
3. Lin CC, Li TC, Lai MM, Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005; 153: 679–686.
4. Pedersen TR, Olsson AG, Fćrgeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453–1460.
5. Wang TD, Chen WJ, Chien KL, Su SSY, Hsu HC, Chen MF. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am J Cardiol 2001; 88: 737–743.
6. Buchwald H, Boen JR, Nguyen PA, Williams SE, Matts JP, Plasma lipids and cardiovascular risk: a POSCH report. Atherosclerosis 2001; 154: 221–227.
7. Manninen V, Tenkanen L, Koskinen P, Huttenen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrating on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37–45.
8. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfiled M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477–484.